Results 191 to 200 of about 25,411 (262)

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? [PDF]

Eur Heart J Cardiovasc Pharmacother
Komiyama M, Hasegawa K, Rosano GMC.
europepmc   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]

Cureus
George V, Pillai MH, Jacob V, Mp R, Vasant A, Adnan H.   +5 more
europepmc   +1 more source

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists. [PDF]

Cureus
Okunlola AO, Kolawole O, Otabor E, Hassan A, Hamilton M, Alomari L, Lam J, Idowu AB.   +7 more
europepmc   +1 more source

In Silico Investigation of Mineralocorticoid Receptor Antagonists: Insights into Binding Mechanisms and Structural Dynamics. [PDF]

Molecules
Liang JJ, Cao S, Hung A, El-Osta A, El-Osta A, Karagiannis TC, Young MJ.   +6 more
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Zaheen M, Ferdous F, Amarasekera AT, Petutschnigg J, Edelmann F, Tan TC.   +5 more
europepmc   +1 more source

Monitoring renal safety in mineralocorticoid receptor antagonist trials [PDF]

European Journal of Heart Failure, 2017
openaire   +2 more sources

Recent advances in mineralocorticoid receptor antagonists for heart failure with preserved ejection fraction: focus on finerenone in the era of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. [PDF]

Front Pharmacol
Wang TY, Zhang L, Wang HY, Jiang FF.
europepmc   +1 more source

Mineralocorticoid Receptor Antagonists and Cognitive Outcomes in Cardiovascular Disease and Beyond: A Systematic Review. [PDF]

J Pers Med
Pastena P, Campagnoli G, Rahmani AR, Kalogeropoulos AP.   +3 more
europepmc   +1 more source